Barclays lowered the firm’s price target on Abbott to $140 from $141 and keeps an Overweight rating on the shares. The company’s strong operating performance and upside to Street estimates was overshadowed by concerns over the ongoing litigation related to pediatric nutrition, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott Q1 strong but still in penalty box on litigation overhang, says Bernstein
- Abbott price target lowered to $125 from $128 at RBC Capital
- Abbott price target lowered to $124 from $127 at Raymond James
- 3 Best Stocks to Buy Now, 4/18/2024, According to Top Analysts
- Abbott says performance of business continues to be ‘very strong’
